CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

Group 1 - Gene therapy stocks, including CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA), experienced significant volatility in Q1 2025, resulting in year-to-date share price declines of -2.82% and -24.19%, respectively [1] - The decline in share prices may be partially linked to the overall instability in the biotechnology sector [1] - The analysis focuses on the potential of novel treatments, particularly in Cell & Gene Therapies (CGT), and their ability to generate returns for shareholders [1]